Costa-Mallen Paola, Zabetian Cyrus P, Agarwal Pinky, Hu Shu-Ching, Yearout Dora, Samii Ali, Leverenz James B, Roberts John W, Checkoway Harvey
Bastyr University Research Institute, Kenmore, WA, USA.
Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
Parkinsonism Relat Disord. 2015 Sep;21(9):1087-92. doi: 10.1016/j.parkreldis.2015.07.006. Epub 2015 Jul 10.
Haptoglobin is a hemoglobin-binding protein that exists in three functionally different phenotypes, and haptoglobin phenotype 2-1 has previously been associated with Parkinson disease (PD) risk, with mechanisms not elucidated. Some evidence is emerging that low levels of serum iron may increase PD risk. In this study we investigated whether PD patients have lower serum iron and ferritin than controls, and whether this is dependent on haptoglobin phenotype. We also investigated the effect of Hp phenotype as a modifier of the effect of smoking on PD risk.
The study population consisted of 128 PD patients and 226 controls. Serum iron, ferritin, and haptoglobin phenotype were determined, and compared between PD cases and controls. Stratified analysis by haptoglobin phenotype was performed to determine effect of haptoglobin phenotype on serum iron parameter differences between PD cases and controls and to investigate its role in the protective effect of smoking on PD risk.
PD cases had lower serum iron than controls (83.28 ug/100 ml vs 94.00 ug/100 ml, p 0.006), and in particular among subjects with phenotype 2-1. The protective effect of smoking on PD risk resulted stronger in subjects with phenotype 1-1 and 2-2, and weakest among subjects with phenotype 2-1. Ferritin levels were higher in PD cases than controls among subjects of White ethnicity.
Our results report for the first time that the haptoglobin phenotype may be a contributor of iron levels abnormalities in PD patients. The mechanisms for these haptoglobin-phenotype specific effects will have to be further elucidated.
触珠蛋白是一种血红蛋白结合蛋白,存在三种功能不同的表型,此前已发现触珠蛋白2-1表型与帕金森病(PD)风险相关,但其机制尚未阐明。有证据表明血清铁水平低可能增加PD风险。在本研究中,我们调查了PD患者的血清铁和铁蛋白水平是否低于对照组,以及这是否取决于触珠蛋白表型。我们还研究了触珠蛋白表型作为吸烟对PD风险影响的调节因素的作用。
研究人群包括128例PD患者和226例对照。测定血清铁、铁蛋白和触珠蛋白表型,并在PD病例和对照之间进行比较进行。通过触珠蛋白表型进行分层分析,以确定触珠蛋白表型对PD病例和对照之间血清铁参数差异的影响,并研究其在吸烟对PD风险的保护作用中的作用。
PD病例的血清铁低于对照组(83.28μg/100ml对94.00μg/100ml,p<0.006),尤其是在2-1表型的受试者中。吸烟对PD风险的保护作用在1-1和2-2表型的受试者中更强,在2-1表型的受试者中最弱。在白人种族受试者中,PD病例的铁蛋白水平高于对照组。
我们的结果首次报告触珠蛋白表型可能是PD患者铁水平异常的一个因素。这些触珠蛋白表型特异性效应的机制有待进一步阐明。